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How did the study come about?
Background
Crohn’s disease, ulcerative colitis and indeterminate
colitis are the three subtypes of disease collectively
known as inflammatory bowel diseases: relapsing and
remitting conditions characterized by chronic inflam-
mation which is limited to the colon in ulcerative colitis,
whereas it can involve various sites in the gastro-
intestinal tract in Crohn’s disease.1 The pathogenesis of
inflammatory bowel disease is currently still unclear,
although humoral and cell-mediated immune system,
as well as environmental [hygiene, smoking, non-
steroidal anti-inflammatory drugs (NSAIDs) use, geo-
graphic location] and genetic factors are known to be
involved in the occurrence of these diseases.
Patients often require continuous medication as well
as one or more intestinal resections. The care of these
patients is evolving rapidly with the introduction of
novel therapies and treatment plans.2,3 Some of these
new treatments are expensive and their efficacy is
usually limited to 30–50% of patients. In the absence
of markers able to predict response to specific
therapies, all eligible patients currently receive several
of these drugs. They are thus exposed to side-effects
which contribute to the high overall cost of these
therapies—half the average medical costs associated
with the disease,4,5—while only a fraction of those
treated will benefit at each stage.
Impact on patient quality of life is often consider-
able, especially because disease onset can occur
already in the first or second decade of life, while
patients are either in full-time education or just
entering the workforce. The negative impact on social
life or ability to achieve, either scholastically or
professionally, can severely affect professional as
well as family life. Indeed, 450% of patients with
Crohn’s disease indicate that their disease has an
influence on their professional and personal life.6 The
course of the disease is often characterized by
progressive worsening of the patient’s condition,
with increasing frequency of hospitalization and
considerable indirect costs through absenteeism and
disability allowances.7 Disease activity is known to be
influenced by psychological factors.8–10
Pilot study
In a first phase, an adult, population-based cohort was
established in the Canton of Vaud (Switzerland)
between July 2003 and December 2004 in order to
make an estimation of the prevalence of inflammatory
bowel disease patients. Among this population of
650 000 inhabitants (about a tenth of the Swiss
population, with similar age and sex distribution),
1016 adult inflammatory bowel disease patients were
identified,11 corresponding to an age- and sex-adjusted
prevalence of 206 inflammatory bowel disease cases per
105 inhabitants. Extrapolating from these figures to the
whole of Switzerland, the number of adults with infla-
mmatory bowel disease could be estimated to be about
12 000, i.e. rather high compared with reported rates in
Europe and North America over the last 20 years.12–18
The study was extended to all of Switzerland in
2006, in a collaborative and multidisciplinary effort by
gastroenterologists, pathologists, psychologists and
methodologists, and with the financial support of
the Swiss National Science Foundation (SNSF).
What does it cover?
The general aim of the SIBDCS is to provide the Swiss
and international scientific, public health and medical
community with a disease-oriented prospective cohort
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of inflammatory bowel disease patients. Data from
the Swiss IBD cohort (SIBDC) will (i) provide up-to-
date epidemiological data (e.g. prevalence, incidence,
clinical course of inflammatory bowel diseases) and to
investigate risk factors associated with favourable or
unfavourable evolution of the course of the disease;
(ii) document medical care given to the patient in
order to assess appropriateness of care; (iii) evaluate
current health resource consumption (direct and
indirect costs) for inflammatory bowel disease
patients and the influence of new biological therapies,
in order to optimize costs and public health policies
for chronic diseases; and (iv) study psychosocial
aspects linked to the disease, by seeking predictors
associated with inflammatory bowel disease exacer-
bation, as well as investigating the role of cytokines in
the pro-inflammatory response to stress.
A biobank has been set up to collect serum, blood
lymphocyte and DNA samples to allow better identi-
fication of clinical or biological markers able to predict
response to specific therapies.
A number of nested projects on various specific
aspects linked to inflammatory bowel disease and the
cohort study are proposed each year. The most
promising projects will be funded within the frame-
work of the cohort, but additional, independently
funded projects may be proposed as well.
Who is in the sample?
Because access to patient chart data from all of the
250 gastroenterologists in Switzerland is difficult to
obtain, there is no intention to recruit all patients
with inflammatory bowel disease in the whole of
Switzerland. In addition, there is no centralized
administrative database that could assist in case
identification. There is no financial incentive for the
gastroenterologists to participate in the
cohort; participation is voluntary, relying on individ-
ual motivation, especially for those working in private
practice and outside the university hospital setting.
Despite these obstacles, we plan to be able to
assemble a large clinical cohort in Switzerland.
Within this framework, we will also assemble a
population-based clinical cohort and recruit all
patients with inflammatory bowel disease in two
specific geographic regions corresponding to the
cantons of Vaud and Solothurn (910 000 total
inhabitants at the end of 2006). Indeed, a pilot
study has already taken place in the Canton of Vaud,
meaning that coverage is thus virtually complete.
Participation is not restricted by age or sex.
Permanent residence status in Switzerland or having
contracted Swiss health insurance and being treated
on a regular basis in Switzerland are, however, a
requirement for study inclusion. This means that
individuals who are treated in Switzerland, but who
are not residents, most commonly cross-border
workers from France, are included in the cohort. To
be included, patients must have a diagnosis estab-
lished at least 4 months prior to inclusion or have had
at least one recurrence of the symptoms. Diagnosis,
based on Lennard-Jones criteria,19 can be confirmed
by radiological, endoscopic and histological findings,
or surgery.
One thousand and twenty patients have been
recruited as of June 30, 2008, the goal being to include,
within 3 years, 3000 patients from anywhere in
Switzerland with any diagnosis of Crohn’s disease,
ulcerative colitis or indeterminate colitis. Given the
diversity of projects included in the cohort study
(appropriateness of care; economics of IBD; psycho-
social correlates of relapse; in addition to smaller nested
projects), it is not possible to calculate a unique cohort
sample size, as this would be linked to the research
hypothesis of each of these projects. For example, a
sample size of 950 patients with Crohn’s disease would
be needed to detect a 10% difference in proportion of
patients having appropriate therapy, depending on
whether they were being treated with steroids or
biologicals, to maintain disease remission.
Recruitment first began in the six major inflamma-
tory bowel disease centres of the university-based
tertiary hospitals. Each participating centre has a local
coordinator and a study nurse/clinical research assis-
tant, who is responsible for recruitment organization
in a defined region (Figure 1), called working areas.
The working areas were defined according to affinities
between regional gastroenterology networks and
university centres. Recruitment is fostered by provid-
ing information about the study and contacting
gastroenterologists by mail or through informational
meetings, either in regional or canton hospitals or in
private practices. The local coordinator organizes
biosample collection and processing in collaboration
with the central biobank and is responsible for quality
control of information provided on biosample
tube labels and forms sent with the specimens.
Recruitment of inflammatory bowel disease patients
is carried out by their gastroenterologist, either during
a routine visit or by mail invitation. A further channel
of information about the study exists through patient
organizations [ASMCC (Association Suisse de la
Maladie de Crohn et de la Colite ulce´reuse)/SMCCV
(Schweizerische Morbus Crohn/Colitis ulcerosa
Vereinigung)], so that patients can be recruited
independently, for example those who have been in
remission for a long time and who do not currently
require any medical attention.
The study required approval by all ethics committees
in Switzerland. In all, 14 cantonal or regional ethics
committees had to be contacted in the 26 Swiss
cantons, to cover the whole country. Eight cantons
had their own local committee and the other 18 were
covered by 6 committees serving regions comprising
2–6 cantons. Approval has so far been obtained in all
but four cantons.
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How often is the follow-up?
All patients (adult and paediatric) are followed up
once a year. An annual medical examination is
planned with the gastroenterologist for this purpose,
in order to update the patient’s medical record with
any changes that have occurred during the previous
year. In addition, an annual questionnaire is sent to
the patient to collect information about events that
have occurred during the previous year (hospitaliza-
tion, new therapies) and to update the psychosocial
situation (repeat measurements of quality of life,
depression and anxiety) and clinical evolution (dis-
ease activity). Gastroenterologists are also encouraged
to report any relevant events occurring at any time, by
completing an ‘unscheduled event’ form, a one-page
document referring to any incident in the patient’s
disease evolution (flare, hospitalization) or significant
treatment modifications.
For the paediatric part of the cohort, physician
questionnaires have been adapted for paediatric
patients, i.e. using severity scores of disease specially
developed for this population, and the patient ques-
tionnaires were divided into two parts, one that will
be completed with the child during a structured
interview conducted by a research assistant and one
to be completed by the parents.
What is being measured?
At the initial visit, the patient’s gastroenterologist
checks the eligibility of the patient for the study
(screening form) and then completes the enrolment
form. The gastroenterologist fills in the current
disease status part of the enrolment questionnaire,
but can request the assistance of a study nurse to
complete the part concerning past medical history.
Variables collected include severity and location of the
disease, current and past therapies, factors that may
play a role in the pathogenesis of the disease
(smoking status, non-steroidal anti-inflammatory
drugs), complications and surgery.
By signing the appropriate informed consent form,
eligible patients confirm their participation in the
cohort study at the time of enrolment and give their
consent to blood and tissue sample collection for
research purposes. If the patient agrees to biosample
collection, blood samples and biopsies are collected
within 3 weeks of enrolment and sent to the SIBDCS
biobank to be stored and processed for specific
research projects.
A questionnaire, in French or German, is then sent
to the patient in order to collect socio-demographic
data as well as information about ethnicity, disability,
hospital stays, medical consultations and history of
joint pain. Elements concerning psychosocial well-
being, which are presumed to be related to or to
influence the exacerbation of the disease are also
collected through 10 specific standardized question-
naires which focus on areas such as quality of life,
social environment, stress, mood and personality.
If the patient is hospitalized, a short supplementary
questionnaire concerning hospital resource consump-
tion is completed by the study nurse.
The questionnaires used for the study are listed
in Table 1. A summary of the variables collected
and frequency of data collection is given in Table 2,
Figure 1 Location of the six major centres of inclusion and their working areas
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with indications concerning the related questionnaires
and frequency of collection (unique/repeated
measurements).
What will be the major areas of
research?
Firstly, we aim to provide up-to-date epidemiological
data (e.g. prevalence, incidence, clinical course of
inflammatory bowel diseases) and investigate risk
factors associated with favourable or unfavourable
evolution of the course of the disease. We also plan to
be able to investigate risk factors associated with
disease by comparison with an external population-
based cohort, the CoLaus study,20 which studies
cardio-vascular risk factors and new genetic determi-
nants in the population of Lausanne, Canton of Vaud,
Switzerland.
Appropriateness of care
Information on appropriateness of care and the
impact of medical management on medium- to
long-term general patient outcome is lacking in
inflammatory bowel diseases. Existing observational
long-term follow-up data has been limited to specific
therapies or to specific complications such as the
development of cancer.21–23 As a result, decision-
making on the use of the various available therapies
is based mainly on results of randomized trials that
include a limited number of patients, with little
knowledge as to whether the treatment favourably
modifies disease outcome and overall patient health.
In addition to being crucial for individual patient
management, global long-term outcome information
is central to decision-making in health economics and
this project will thus fill gaps in our scientific
knowledge in a timely fashion.
Up-to-date criteria on appropriateness of care for
Crohn’s disease patients were recently developed
using the RAND/UCLA Appropriateness Method.24,25
Applying these criteria as an observational tool allows
assessment of appropriateness of care at baseline and
examination of the possibilities for its systematic
improvement prospectively.26 Moreover, various phar-
maceutical agents will be compared to each other in
terms of safety and effectiveness, and overall manage-
ment strategies applied to patient groups within the
cohort. The role of surgery in the care of these
patients is changing27 and its current use will be
documented in comparison to medical therapy.
Economic aspects
The second core project evaluates resource consump-
tion (direct and indirect costs) and cost of new
biological therapies.4,5,7 Indeed, studies exist which
show a significant influence of these novel drugs on
hospitalization and surgical procedures with possible
cost-saving effects.28–30 There is also a possible shift
of the resource demand from inpatient-based man-
agement to outpatient care. We will analyse the cost
of the disease and study the cost-effectiveness of
different interventions, in order to re-assess the
economic impact of inflammatory bowel disease.
A better understanding of these changes is essential
to optimize both individual patient care, resource
allocation by the healthcare system, and impact on
social insurance. The data collected will further
provide valuable information and tools for the
development of a common model for socio-economic
evaluation vs prediction of medical and social
resource consumption in chronic inflammatory dis-
ease in general.
Psychosocial aspects
Psychiatrists have studied patients with inflammatory
bowel disease since the beginning of the 20th century.
Before the introduction of the autoimmune hypoth-
esis in the 1960s and the success of corticosteroids in
inflammatory bowel disease therapy, it was largely
considered to be a psychosomatic disorder.31 Interest
in the role of psychosocial stress in the pathogenesis
and course of these diseases lead to a revival in
behavioural medicine in the last 10 years, with the
advent of the field of psycho-neuro-immunology
(PNI).32 PNI is seen as an interdisciplinary field
studying and integrating interactions between behav-
ioural, neural and endocrine, and immune processes
and appears to be a promising approach to unravel-
ling the contribution of psychosocial stress to immu-
nological diseases such as inflammatory bowel
disease.33
This major objective of the project is thus based on
the relationship between psychosocial risk factors and
steady-state inflammatory activity in inflammatory
bowel disease patients. Secondly, stress reactivity of
pro-inflammatory markers in such patients will be
Table 1 SIBDCS questionnaires and person responsible
for providing the information
Questionnaire nme
Responsible for
completion
Screening sheet (S) Physician
Enrolment (E) Physician/Study nurse
Initial patient questionnaire
(P1/Faor Ga)
Patient
Biosamples (B) Physician/Study nurse
Unscheduled event sheet (UE) Physician
Hospital resources consumption (H) Study nurse
Annual follow-up (AF) Physician/Study nurse
Annual follow-up qestionnaire
(FUP/Faor Ga)
Patient
Stop Form Physician
aF, French version; G, German version.
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Table 2 SIBDCS variables and informants [Physician, Patient or specific questionnaires] at inclusion, at annual
follow-up or linked to specific unscheduled events
Questionnaire
Frequency of
data collection
Measurements Physician Patient Specific
At
inclusion
Annual
FU
Unscheduled
event
Inclusion and exclusion criteria S X
Diagnosis X X S X X
Diagnosis (duration of symptoms, duration of disease) X X X
Clinical course X X
Current disease location X X X
Initial disease location and methods of assessment X X
Severity of disease X X X
Laboratory values X X X
Current therapy (Specific to IBD; dietary
supplementation; alternative medicine)
X X UE X X
Previous therapies X X X
Adverse events report X X
Clinical situation (working hypothesis) X UE X X X
Management decision X UE X X X
Previous medical visits and exams X X
New exams X UE X X
Current smoking status X X X X
Smoking status at diagnosis X X X
NSAIDs consumption at diagnosis X X X
Family history of IBD X X X
Complications X UE X X X
Extraintestinal manifestations X X X
Fistula/Abscess X X X
Stenosis X X X
New hospitalization X UE, H X X
Previous hospitalization X X X
Previous rehabilitation clinic stays X X
Surgery X X UE, H X X X
Specific questions about medical history
(TBC vaccination, appendicectomy,
coeliac disease, psoriasis)
X X
Indication for colonoscopy B X X X
Endoscopy findings B X X X
Disease activity B X X X
Demographic data/ethnicity X X
Socioeconomic data (education, occupation) X X X
Degree of disability X
Life-habits (Jenkins Sleep Questionnaire,
sport, alcohol consumption)
X X X
Rheumatological pain X X X
Psychosocial Questionnaires
Inflammatory Bowel Disease
Quality of life Questionnaire (IBDQ)
X X X
(continued)
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compared with controls in order to identify the
predictors of disease exacerbation. This will constitute
an important step towards better understanding of
some of the bio-behavioural links between stress and
disease activity in humans. Understanding the basic
psychophysiology of human diseases requires rigorous
inclusion criteria to prevent confounding of biological
measures (e.g. cytokines) by many factors, including
pre-analytical factors.34,35 The recruitment of a sub-
cohort of selected patients to perform cytokine and
stress studies with negligible confounding will be
possible because of the large number of patients
included in the cohort study.
Biobank
In addition to clinical and patient-reported data, a
central biobank collects serum, blood lymphocyte and
DNA samples. As the biobank is closely linked to the
large volume of patient information, unique genetic
and immunological correlations with patient pheno-
type, response to therapy, clinical course and outcome
are foreseen. The recognition of the crucial role of
genetically encoded variants of proteins critically
involved in bacterial antigen recognition, such as the
products of Crohn’s disease-associated NOD2/CARD15
mutations, is now regarded as a central event in
the immunopathological cascade that characterizes
Crohn’s disease. In ulcerative colitis, the genetic base
is less well characterized, but gene involvement, in
particular in HLA-compatibility genes, may contribute
to disease pathogenesis.
Nested projects
Two nested projects are currently linked to the
SIBDCS. The first examines the pharmacogenetics of
drug transporters and nuclear receptors in inflamma-
tory bowel disease. The aim of this project is to
analyse the role of genetic variants of drug transpor-
ters and nuclear receptor genes in determining disease
phenotype and response to pharmacological treatment
in patients with inflammatory bowel disease.36–38
The second nested project concerns the association
of clinical subgroups of inflammatory bowel disease
patients with Mannan-binding lectin (MBL) geno-
types and humoral immune responses.39 The objective
is to obtain further information on the clinical
significance of MBL deficiency using a nationwide
cohort of inflammatory bowel disease patients.
Response rate and expected
attrition
The response rate of patients to the initial patient
questionnaire is currently about 76% (n¼ 851 as of
June 30, 2008), but this proportion will, in fact,
probably be slightly greater as mailings and reminders
are sent throughout the year. This point estimation
takes into account those who only received the
questionnaire a short time ago, as well as those who
received a first reminder. In case of non-response
after 3 months, a first reminder is sent, followed by a
second one in which it is suggested that the patient
contacts a study nurse to help them fill in the
questionnaire if necessary. If the patient does not
respond to the second reminder, the study nurse
attempts to make contact by telephone, in order to be
able to ascertain the reason for non-response as a
minimum. Based on current returns following two
reminders, it is anticipated that close to 90% of
patients will return the patient questionnaire. Patients
who did not reply to the two reminders or who could
not be contacted by telephone by the study nurse, will
be considered as lost to follow-up. Patients can be
considered as excluded or withdrawn for several
reasons, such as change of diagnosis (no more
inflammatory bowel disease), withdrawal of consent
or emigration.
Table 2 Continued
Questionnaire
Frequency of
data collection
Measurements Physician Patient Specific
At
inclusion
Annual
FU
Unscheduled
event
SF-36 X X X
Hospital Anxiety and Depression Scale (HADS) X X X
Enhancing Recovery in Coronary Heart Disease
Patients Social Support Inventory (ENRICHD SSI)
X X
Type D Personality (DS-14) X X
Over-commitment Questionnaire X X
Coping Inventory for Stressful Situations short form (CISS) X X
Perceived Stress Questionnaire (PSQ) X X
Post-traumatic Diagnostic Scale (PDS) X X
Effort-Reward-Imbalance questionnaire (ERI) X X
S, screening sheet; UE, unscheduled event sheet; H, hospital resource consumption; B, biosample form.
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The SIBDCS will encourage and maintain the
participation by physicians and patients by providing
them with annual information and feedback. In
addition, it is planned that a physician- and patient-
newsletter will be sent to them, as well as posting it
on the study website.
Each year, gastroenterologists who enrol patients
will receive a certificate of participation in the
SIBDCS, and since November 1, 2007, a cohort
member card has been sent to patients, with a unique
cohort number to be shown each time they visit the
gastroenterologist or in case of hospitalization, which
will also assist in avoiding double-entry. Furthermore,
a ‘Swiss IBD Day’ conference has been introduced to
encourage participation by providing appropriate
content for practitioners, researchers and patients.
What has been found so far?
Since November 2006, the six major inflammatory
bowel disease university centres have begun to recruit
patients. Figure 2 shows the number of patients
enrolled per month up to June 2008 and the
cumulative number of patients enrolled. For the first
year, the expected number of patients enrolled was
1000, corresponding to a mean of 83 per month. A
total of 1120 patients were enrolled as of end June
2008, 670 (59.8%) suffering from Crohn’s disease, 419
(37.4%) from ulcerative colitis and 31 (2.8%) with the
diagnosis of an indeterminate colitis. The proportion
of cases according to gender and type of disease is
given in Table 3. Globally, there is an equal gender
proportion for both Crohn’s disease and ulcerative
colitis patients.
The mean age of the cohort population is 43 years
(15), ranging from 7 to 89 years. The diagnosis of
the Crohn’s disease patients was established at least 4
months prior to inclusion in 95% of cases; 66% were
diagnosed after at least one recurrence. The method of
diagnostic assessment for Crohn’s disease or ulcera-
tive colitis was endoscopy with biopsies in the
majority of patients (96%, 99%, respectively), and/or
surgery (29%, 8%, respectively) or radiological studies
(26%, 12%, respectively).
Seventy-six percent of patients have already
responded and 13% are currently expected to respond,
i.e. they received the questionnaire <3 months ago.
Only 11% of patients did not reply to the first
reminder, and it is planned that the local study
nurse will contact them in the near future.
Figure 2 shows a slight tendency towards a decrease
in the number of patients enrolled. This is linked to
the fact that during the first year most patients
were enrolled in the major centres and less in
regional hospitals and in private practices. It is planned
that regular information meetings conducted by
study nurses and local clinical investigators to give
up-to-date information on the cohort study will
bring other gastroenterologists and patients into the
study.
What are the main strengths
and weaknesses?
The SIBDC is a disease-oriented prospective cohort. It
will not be entirely population-based, except for
specific geographic regions, e.g. the Cantons of Vaud
and Solothurn. This is a limitation of the study
because comparisons with non-inflammatory bowel
disease cases would only be possible using data from
external research groups. The decentralized organiza-
tion of the Swiss healthcare system precludes achiev-
ing comprehensive coverage of all cases in the country
for inflammatory bowel disease, whereas broader
coverage was achieved by the Swiss HIV cohort40
because almost all cases are referred to dedicated
specialist clinics.
Our study includes both children and adult patients,
and specific questionnaires were designed for each
category, specifically taking into account severity-of-
disease measurements, psycho-social factors and
quality of life. The inclusion of patients of all ages
constitutes a strength of the study of these chronic
diseases which not infrequently begin in adolescence
and early adulthood.
The SIBDCS encompasses research input
from different fields and medical disciplines
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Figure 2 Cumulative number of SIBDCS patients
included from November 2006 to June 2008
Table 3 Type of disease according to gender
Gender
Type of diagnosis Male Female Total
Crohn’s disease 218 (47%) 244 (53%) 462 (62%)
Ulcerative colitis 138 (50%) 137 (50%) 275 (36%)
Indeterminate colitis 9 (53%) 8 (47%) 17 (2%)
Inflammatory bowel
disease
365 (48%) 389 (52%) 754
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(gastroenterology, internal medicine, psychiatry,
public health, health economics, paediatrics, genetics
and genomics). This is one of its strengths and a
source of mutual enrichment. On the clinical side, the
team of gastroenterologists includes physicians work-
ing in university hospitals as well as in private
practice. This variety of experience was taken into
account in the design of questionnaires (time avail-
able for completion, parts that could be completed
either by the physician or by a nurse), organization
and logistics of enrolment and follow-up. Other
researchers involved at the data centre are statisti-
cians, epidemiologists and computer scientists.
Pathologists have set up a biobank for collecting
samples that can be stored for specific genetic
analysis.
Can I have access to the data?
Where can I find out more about
the study?
All data are organized and centralized at the data
centre, attached to the Lausanne Institute of Social
and Preventive Medicine. All logistic aspects of the
data flow are managed through the centre, as well as
data control and statistical analyses. Information and
summary results are provided to the participating
gastroenterologists in the form of a report which
comprises three parts: (i) an individual feedback
sheet, established for each patient, which contains a
summary of the information collected via physician
questionnaires over the past year; (ii) a summary and
basic descriptive analysis of the physician’s group of
patients and for the whole cohort; and (iii) it is
planned that the global results giving summary
information on the whole cohort will be accessible
on the website of the SIBDCS, currently under
construction (http://www.ibdcohort.ch).
A manual of Guidelines for Submission and
Evaluation of Project Proposals has been prepared by
the Scientific Board of SIBDCS and it is thus possible to
submit proposals for specific projects that might benefit
from access to anonymous data from the cohort study,
within the limits of ethical considerations, the consent
given by the participating patients and the judicious use
of the cohort resources. All submitted projects are peer-
reviewed and subject to a final decision by the Scientific
Board and the Executive Board.
An external International Scientific Advisory
Committee has been constituted (see appendix) to
provide input on the current state and future
development of the cohort.
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